Orexigen conquers French objections to obesity drug with EU approval
This article was originally published in Scrip
Executive Summary
Orexigen has overcome objections from France to receive European Commission approval for its obesity product Mysimba (naltrexone HCl / bupropion HCl prolonged release) in all 28 EU member states.